The FDA has once again paused clinical trials for Regenxbio’s gene therapy, RGX-121, due to safety concerns raised by abnormal MRI results in five trial participants.
Background on RGX-121
Regenxbio announced that patients who received RGX-121 three to six years ago for Hunter syndrome presented with masses that are “likely” benign, yet no clinical symptoms were reported. These patients have shown stability and even improvement in neurocognitive and neurobehavioral assessments. Despite these positive signs, the FDA’s decision to impose another clinical hold marks a significant regulatory hurdle for the therapy.
Previous Regulatory Setbacks
This latest hold follows a series of setbacks for RGX-121 in 2023. Earlier in the year, the FDA halted testing due to safety issues and subsequently rejected Regenxbio’s application. Following discussions with regulators, the company was preparing to submit a new application. However, given the current circumstances, Regenxbio announced that it would not be filing in the immediate future, leading to a sharp decline of over 25% in their stock price during early trading on Monday.
The Journey of RGX-121
RGX-121 aims to provide a one-time treatment solution for Hunter syndrome, a genetic disorder affecting the body’s ability to metabolize sugar molecules. While clinical trials indicated its potential to reduce disease markers, the program faced difficulties after a participant receiving a closely related treatment developed brain cancer. This incident prompted the FDA to delay approval decisions and ultimately reject Regenxbio’s application, citing insufficient evidence for the trial’s surrogate endpoint.
Seeking a Path Forward
In response to the FDA’s rejection, Regenxbio sought to appeal the decision and initiated an urgent “Type A” meeting to discuss the results. This meeting yielded an agreement on the necessary steps for achieving accelerated approval, which would allow for a faster review based on limited evidence. Regenxbio had aimed to resubmit its application in June, but the recent hold has cast uncertainty over the therapy’s future.
Understanding the MRI Findings
Regenxbio has emphasized that there is currently no clinical or pathological evidence linking the MRI findings to RGX-121. Notably, no brain masses or nodules were observed in the patients. The company pointed out that, as spine MRIs are not typically conducted on Hunter syndrome patients, the significance of these asymptomatic findings remains unclear.
Future Developments
Regenxbio, in partnership with NS Pharma, is actively reviewing the data related to the MRI findings and will incorporate feedback from the FDA into their developmental strategy moving forward. The outcome of this evaluation could be pivotal in shaping the future of RGX-121.
Conclusion
The future of Regenxbio’s RGX-121 gene therapy hangs in the balance as the company navigates regulatory challenges and safety concerns. With ongoing evaluation and potential adjustments in strategy, the path forward remains uncertain but critical for those affected by Hunter syndrome. The coming months will be crucial for Regenxbio as it seeks to address these concerns and work towards a viable solution.
- Key Takeaways:
- FDA halts RGX-121 trials due to MRI abnormalities.
- Previous regulatory setbacks include a testing pause and application rejection.
- The therapy aims to treat Hunter syndrome, a rare genetic disorder.
- Regenxbio is reviewing data and FDA feedback for future steps.
Read more → finance.yahoo.com